Profile data is unavailable for this security.
About the company
Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.
- Revenue in USD (TTM)0.00
- Net income in USD-76.41m
- Incorporated2009
- Employees88.00
- LocationAura Biosciences Inc80 Guest StreetBOSTON 01235United StatesUSA
- Phone+1 (617) 500-8864
- Fax+1 (302) 655-5049
- Websitehttps://aurabiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Inc | 130.19m | -24.41m | 367.26m | 315.00 | -- | 5.16 | -- | 2.82 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Tenaya Therapeutics Inc | 0.00 | -124.08m | 367.46m | 140.00 | -- | 2.29 | -- | -- | -1.68 | -1.68 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -55.21 | -- | -61.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Contineum Therapeutics Inc | 50.00m | 22.72m | 368.62m | 31.00 | 15.59 | -- | 16.06 | 7.37 | 0.9041 | 0.9041 | 1.99 | 4.96 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 45.44 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -64.47m | 369.90m | 45.00 | -- | 3.49 | -- | -- | -6.19 | -6.19 | 0.00 | 7.03 | 0.00 | -- | -- | 0.00 | -90.00 | -- | -104.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Erasca Inc | 0.00 | -125.04m | 370.99m | 126.00 | -- | 1.02 | -- | -- | -0.8327 | -0.8327 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -27.48 | -- | -29.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 373.71m | 275.00 | -- | 0.6846 | -- | 1.35 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Alto Neuroscience Inc | 0.00 | -36.31m | 382.29m | 63.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | 2.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1238 | -- | -- | -- | -31.02 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -96.02m | 382.39m | 88.00 | -- | 1.63 | -- | -- | -4.84 | -4.84 | 0.00 | 6.20 | 0.00 | -- | -- | 0.00 | -45.16 | -49.99 | -49.47 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0133 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Aura Biosciences Inc | 0.00 | -76.41m | 390.82m | 88.00 | -- | 1.72 | -- | -- | -1.93 | -1.93 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -31.90 | -- | -33.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Heron Therapeutics Inc | 127.04m | -110.56m | 392.36m | 126.00 | -- | -- | -- | 3.09 | -0.8695 | -0.8695 | 0.9494 | -0.2261 | 0.5367 | 1.35 | 2.26 | 1,008,286.00 | -46.70 | -53.55 | -71.00 | -71.24 | 48.75 | 52.52 | -87.02 | -170.12 | 1.84 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Esperion Therapeutics Inc | 116.33m | -209.25m | 393.95m | 240.00 | -- | -- | -- | 3.39 | -2.11 | -2.11 | 1.13 | -3.85 | 0.5128 | 0.8583 | 2.83 | 484,725.00 | -92.23 | -69.45 | -203.94 | -101.81 | 62.81 | -- | -179.87 | -147.44 | 0.867 | -2.85 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| ADC Therapeutics SA | 69.56m | -240.05m | 405.79m | 273.00 | -- | -- | -- | 5.83 | -2.94 | -2.94 | 0.8528 | -1.80 | 0.1645 | 0.179 | 1.42 | 254,791.20 | -55.47 | -48.41 | -67.39 | -55.63 | 96.36 | -- | -337.16 | -308.62 | 4.73 | -4.70 | 1.55 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Tourmaline Bio Inc | 0.00 | -42.12m | 406.24m | 44.00 | -- | 1.57 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -44.60m | 407.37m | 19.00 | -- | -- | -- | -- | -10.38 | -10.38 | 0.00 | -1.56 | 0.00 | -- | -- | 0.00 | -94.31 | -86.84 | -178.23 | -130.46 | -- | -- | -- | -769.76 | -- | -15.46 | 1.74 | -- | -- | -- | -5.33 | -- | -- | -- |
| Anika Therapeutics Inc | 166.66m | -82.67m | 409.12m | 357.00 | -- | 1.91 | -- | 2.45 | -5.64 | -5.64 | 11.37 | 14.48 | 0.5378 | 1.48 | 4.72 | 466,840.30 | -26.68 | -5.41 | -29.48 | -5.87 | 61.85 | 60.70 | -49.60 | -12.60 | 3.76 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Revance Therapeutics Inc | 234.04m | -323.99m | 411.65m | 534.00 | -- | -- | -- | 1.76 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Data as of May 03 2024. Currency figures normalised to Aura Biosciences Inc's reporting currency: US Dollar USD
59.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 31 Dec 2023 | 6.92m | 14.07% |
| Eventide Asset Management LLCas of 31 Dec 2023 | 5.80m | 11.80% |
| Adage Capital Management LPas of 31 Dec 2023 | 4.23m | 8.59% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.57m | 7.25% |
| Lundbeckfond Invest A/Sas of 31 Mar 2023 | 2.02m | 4.10% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.94m | 3.95% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.70m | 3.46% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 1.32m | 2.69% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 1.04m | 2.11% |
| Regency Capital Management, Inc.as of 31 Dec 2023 | 704.97k | 1.43% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
